Clinical heart research with translational aspects focusing on patients with acute ST-elevation myocardial infarction (STEMI) or cardiac arrest admitted to the cardiac intensive care unit (CICU).
Primary objectives:
To explore in detail the pathogenesis of acute coronary syndromes ((ACS) including STEMI) and ischemia-reperfusion injury with focus on how systemic and local inflammation may potentially contribute to plaque destabilization and myocardial damage.
Interventional studies targeting ischemia/reperfusion injury aiming to reduce infarct size
Treatment of acute heart failure and cardiogenic shock complicating STEMI
Prognostication, monitoring and treatment of patients with out-of- hospital cardiac arrest in order to improve survival and neurological prognosis
Obtain new mechanistic insights on the importance of residual inflammation on patients with ACS, open the way for novel treatment and prevention options
Woxholt S, Ueland T, Aukrust P, Anstensrud AK, Broch K, Tøllefsen IM, Seljeflot I, Halvorsen B, Dahl TB, Huse C, Andersen GØ, Gullestad L, Wiseth R, Damås JK, Kleveland O(2024) Effect of tocilizumab on endothelial and platelet-derived CXC-chemokines and their association with inflammation and myocardial injury in STEMI patients undergoing primary PCI Int J Cardiol, 418, 132613(in press) DOI 10.1016/j.ijcard.2024.132613, PubMed 39374793
Nendl A, Andersen GØ, Seljeflot I, Trøseid M, Awoyemi A(2024) Intestinal fatty acid binding protein is associated with infarct size and cardiac function in acute heart failure following myocardial infarction Open Heart, 11(2) DOI 10.1136/openhrt-2024-002868, PubMed 39277188
Kindberg KM, Broch K, Andersen GØ, Anstensrud AK, Åkra S, Woxholt S, Tøllefsen IM, Ueland T, Amundsen BH, Kløw NE, Halvorsen B, Dahl TB, Huse C, Murphy SL, Damås JK, Opdahl A, Wiseth R, Gullestad L, Aukrust P, Santos-Gallego C, Seljeflot I, Stokke MK, Helseth R(2024) Neutrophil Extracellular Traps in ST-Segment Elevation Myocardial Infarction: Reduced by Tocilizumab and Associated With Infarct Size JACC Adv, 3(9), 101193 DOI 10.1016/j.jacadv.2024.101193, PubMed 39247678